Express News | AnaptysBio Inc - Year-End 2024 Cash About $415 Mln
Express News | AnaptysBio Inc - Anb032 Well Tolerated With No Safety Signals Observed
Express News | AnaptysBio Inc - Anb032 Ad Trial and All Further Investment Will Be Discontinued
Express News | AnaptysBio Inc: Anticipate Top-Line Phase 2B Data in Rheumatoid Arthritis in February 2025
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Express News | Anaptys Announces Phase 2B Trial of Anb032, a Btla Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
HannChau : short it i guess
HannChau HannChau : cant short because it is suspended.